Correction: A Systems Genetics Approach Identifies CXCL14, ITGAX, and LPCAT2 as Novel Aggressive Prostate Cancer Susceptibility Genes

摘要

The authors made an error in analysis, with SNPs being mapped to human genome build hg18 and genes to human genome build hg19. Consequently, there are errors in Table 5 , S15 Table , and the accompanying text on pages 9 and 11. Corrected text and tables are provided here. 10.1371/journal.pgen.1005127.t001 Table 5 QTL candidate gene SNPs associated with aggressive prostate cancer in CGEMS GWAS. Chr. Candidate Gene SNP Distance From Gene (bp) SNP PLCO Variable Odds Ratio (95% C.I.) Minor Allele Frequency t stat P value Permutation P value Aggressive Disease Non-Aggressive Disease 5q31.1 CXCL14 0 rs2547 pros_gleason_prost 0.61 (0.43-0.85) 0.054 0.033 -2.889 0.004 0.003 0 rs2237061 pros_gleason_prost 0.61 (0.43-0.88) 0.048 0.030 -2.685 0.007 0.008 19118 rs10515473 pros_gleason_prost 0.72 (0.59-0.88) 0.163 0.122 -3.148 0.002 0.002 24155 rs4463175 pros_gleason_prost 1.42 (1.12-1.81) 0.087 0.101 2.878 0.004 0.003 69386 rs801564 pros_stage_n 1.05 (1.01-1.09) 0.001 0.282 2.587 0.010 0.010 92585 rs2067000 pros_stage_n 1.05 (1.02-1.09) 0.001 0.288 2.883 0.004 0.004 6p22.1 PGBD1 76094 rs1233708 pros_stage 1.08 (1.02-1.13) 0.042 0.213 2.921 0.004 0.003 6p22.2 HIST1H2AB 59345 rs1800562 pros_gleason 1.40 (1.16-1.70) 0.025 0.041 3.459 0.001 0.001 79097 rs933199 pros_gleason 0.75 (0.62-0.92) 0.032 0.025 -2.759 0.006 0.007 6p22.3 GPLD1 43164 rs811103 pros_gleason_prost 1.32 (1.09-1.60) 0.186 0.195 2.855 0.004 0.005 56546 rs793663 pros_gleason_prost 1.32 (1.09-1.60) 0.186 0.195 2.854 0.004 0.006 6q15 AKIRIN2 0 rs4707385 pros_gleason 1.16 (1.05-1.29) 0.135 0.164 2.909 0.004 0.003 ORC3 0 rs6930600 pros_gleason 0.86 (0.78-0.95) 0.246 0.222 -3.095 0.002 0.002 0 rs7755167 pros_gleason 0.86 (0.78-0.95) 0.246 0.221 -3.107 0.002 0.002 0 rs7772351 pros_gleason 1.14 (1.04-1.26) 0.164 0.193 2.768 0.006 0.007 0 rs9450765 pros_gleason 1.17 (1.06-1.29) 0.171 0.202 3.118 0.002 0.002 43692 rs7757636 pros_gleason 0.86 (0.79-0.95) 0.246 0.222 -3.089 0.002 0.003 96943 rs9450716 pros_gleason 1.16 (1.05-1.28) 0.161 0.189 3.042 0.002 0.002 9p13.3 CCL19 70925 rs3802427 pros_stage_m 1.09 (1.04-1.15) 0.000 0.162 3.557 3.89E-04 1.00E-04 CCL21 75161 rs277606 pros_gleason_prost 1.35 (1.11-1.65) 0.179 0.187 2.986 0.003 0.002 KIAA1045 68052 rs10123308 pros_gleason_prost 1.30 (1.08-1.57) 0.212 0.216 2.773 0.006 0.006 9p21.2 MOB3B 0 rs868856 pros_stage 0.94 (0.89-0.98) 0.064 0.215 -2.748 0.006 0.006 0 rs868856 pros_stage_t 2.02 (1.34-3.04) 0.191 0.088 3.371 0.001 0.001 0 rs3739530 pros_gleason 0.80 (0.70-0.93) 0.075 0.056 -2.996 0.003 0.004 0 rs4879515 pros_stage_t 1.68 (1.16-2.41) 0.320 0.130 2.784 0.005 0.005 0 rs7046653 pros_stage_t 2.01 (1.34-3.02) 0.192 0.088 3.346 0.001 0.001 0 rs7046653 pros_stage 0.94 (0.89-0.98) 0.064 0.216 -2.707 0.007 0.007 0 rs10121765 pros_gleason_prost 0.77 (0.64-0.93) 0.260 0.209 -2.776 0.006 0.005 6547 rs2814707 pros_stage_t 2.09 (1.38-3.19) 0.162 0.075 3.458 0.001 0.001 13431 rs3849942 pros_stage_t 2.15 (1.41-3.28) 0.161 0.075 3.564 3.80E-04 0.001 31199 rs774359 pros_stage_t 1.99 (1.32-3.01) 0.176 0.079 3.284 0.001 0.001 64176 rs1853186 pros_stage 0.94 (0.90-0.98) 0.079 0.272 -2.730 0.006 0.006 16p11.2 ITGAX 55680 rs8045738 pros_gleason_prost 1.33 (1.08-1.62) 0.141 0.148 2.753 0.006 0.005 16q12.2 LPCAT2 0 rs10521319 pros_stage_m 1.11 (1.03-1.20) 0.000 0.057 2.619 0.009 0.009 86077 rs9302667 pros_gleason_prost 1.35 (1.11-1.64) 0.156 0.170 2.994 0.003 0.003 98065 rs893260 pros_gleason_prost 1.30 (1.07-1.58) 0.175 0.184 2.679 0.007 0.006 20p11.21 GZF1 52836 rs6076072 pros_stage 0.90 (0.84-0.97) 0.028 0.075 -2.914 0.004 0.003 52836 rs6076072 pros_stage_t 2.17 (1.21-3.92) 0.068 0.035 2.589 0.010 0.009 20p13 NSFL1C 22006 rs6042568 pros_gleason 0.75 (0.62-0.90) 0.037 0.029 -3.007 0.003 0.004 The third paragraph of the section ‘Analysis of Human Prostate Cancer GWAS Data Reveals That QTL Candidate Gene SNPs Are Associated with Aggressive Prostate Cancer’ should read: In the study, 1,372 SNPs mapped within a 100 kb radius of the 29 QTL candidate genes were tested in the CGEMS cohort. Analysis of aggressive vs. non-aggressive disease phenotypes were performed as per the comparisons described in Table 4. Correction for multiple testing was performed using permutation testing (n = 10,000 permutations). Fourteen of the 29 candidate genes exhibited evidence for association with clinical characteristics of aggressive prostate cancer ( Table 5 ). Most notably, SNPs in three of the five genes associated with poor clinical outcomes in TCGA (Provisional) and GSE21032 prostate cancer gene expression datasets ( CXCL14 , ITGAX , and LPCAT2 ) were all associated with aggressive prostate cancer: For CXCL14 , the following SNPs were associated with Gleason score at prostatectomy: rs2547 (permutation P = 0.003; OR = 0.61 [0.43–0.85]), rs2237061 (permutation P = 0.008; OR = 0.61 [0.43–0.88]), rs10515473 (permutation P = 0.002; OR = 0.72 [0.59–0.88]), and rs4463175 (permutation P = 0.003; OR = 1.42 [1.12–1.81]); and the following with metastasis to r